Abbott Laboratories Given Equal Weight Rating at Barclays Capital (ABT)
Barclays Capital reaffirmed their equal weight rating on shares of Abbott Laboratories (NYSE: ABT) in a research note released on Monday morning, Analyst Ratings Network.com reports. They currently have a $35.00 price target on the stock.
Shares of Abbott Laboratories (NYSE: ABT) traded up 1.46% during mid-day trading on Monday, hitting $37.59. Abbott Laboratories has a one year low of $28.4634 and a one year high of $37.55. The stock’s 50-day moving average is currently $36.44. The company has a market cap of $58.598 billion and a P/E ratio of 11.29.
A number of other analysts have also recently weighed in on ABT. Analysts at BMO Capital Markets reiterated an outperform rating on shares of Abbott Laboratories in a research note to investors on Friday, May 3rd. They now have a $40.00 price target on the stock. Separately, analysts at Sanford C. Bernstein reiterated a market perform rating on shares of Abbott Laboratories in a research note to investors on Thursday, May 2nd. They now have a $35.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Abbott Laboratories from $37.00 to $38.00 in a research note to investors on Friday, April 19th. They now have an outperform rating on the stock.
Nine investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $40.23.
Abbott Laboratories (NYSE: ABT) is engaged in the discovery, development, manufacture, and sale of a range of health care products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.